Table 2 Age and sex distribution for the different treatment groups (“concomitant LABA and ICS users”, “switchers”, “non-concomitant LABA and ICS users”, “LABA users without ICS”, “ICS users without LABA”) for the year 2008
From: Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial
Concomitant LABA and ICS users | Switchers | Non-concomitant LABA and ICS users | LABA users without ICS | ICS users without LABA | |
|---|---|---|---|---|---|
N (%) | 177,159 (57.6%) | 14,899 (4.8%) | 1,936 (0.6%) | 16,749 (5.4%) | 96,615 (31.4%) |
Age in years (mean ± SD) | 49.1 ± 21.9 | 59.1 ± 17.8 | 55.4 ± 20.2 | 58.0 ± 19.3 | 37.5 ± 24.9 |
Females (n [%]) | 98,071 (55.4%) | 8,258 (55.4%) | 1,184 (61.2%) | 8,705 (52.0%) | 52,907 (54.8%) |